AI used to predict early symptoms of schizophrenia in relatives of patients
0 Comments
Sunil Kalmady Vasu (centre) led a recent study with fellow U of A researchers including Russ Greiner (left), Andrew Greenshaw (right) and Serdar Dursun (not pictured), showing that a machine learning tool could help predict early symptoms of schizophrenia in siblings and children of patients, potentially leading to earlier diagnosis and treatment. Credit: University of Alberta (taken pre-COVID-19)

University of Alberta researchers have taken another step forward in developing an artificial intelligence tool to predict schizophrenia by analyzing brain scans.

In recently published research, the tool was used to analyze functional magnetic resonance images of 57 healthy first-degree relatives (siblings or children) of schizophrenia patients. It accurately identified the 14 individuals who scored highest on a self-reported schizotypal personality trait scale.

Schizophrenia, which affects 300,000 Canadians, can cause delusions, hallucinations, disorganized speech, trouble with thinking and lack of motivation, and is usually treated with a combination of drugs, psychotherapy and brain stimulation. First-degree relatives of patients have up to a 19 per cent risk of developing schizophrenia during their lifetime, compared with the general population risk of less than one per cent.

“Our evidence-based tool looks at the neural signature in the brain, with the potential to be more accurate than diagnosis by the subjective assessment of symptoms alone,” said lead author Sunil Kalmady Vasu, senior machine learning specialist in the Faculty of Medicine & Dentistry.

Kalmady Vasu noted that the tool is designed to be a decision support tool and would not replace diagnosis by a psychiatrist. He also pointed out that while having schizotypal personality traits may cause people to be more vulnerable to psychosis, it is not certain that they will develop full-blown schizophrenia.

“The goal is for the tool to help with early diagnosis, to study the disease process of schizophrenia and to help identify symptom clusters,” said Kalmady Vasu, who is also a member of the Alberta Machine Intelligence Institute.

The tool, dubbed EMPaSchiz (Ensemble algorithm with Multiple Parcellations for Schizophrenia prediction), was previously used to predict a diagnosis of schizophrenia with 87 per cent accuracy by examining patient brain scans. It was developed by a team of researchers from U of A and the National Institute of Mental Health and Neurosciences in India. The team also includes three members of the U of A’s Neuroscience and Mental Health Institute—computing scientist and Canada CIFAR AI Chair Russ Greiner from the Faculty of Science, and psychiatrists Andrew Greenshaw and Serdar Dursun, who are authors on the latest paper as well.

Kalmady Vasu said next steps for the research will test the tool’s accuracy on non-familial individuals with schizotypal traits, and to track assessed individuals over time to learn whether they develop schizophrenia later in life.

Kalmady Vasu is also using the same principles to develop algorithms to predict outcomes such as mortality and readmissions for heart failure in cardiovascular patients through the Canadian VIGOUR Centre.

“Severe mental illness and cardiovascular problems cause functional disability and impair quality of life,” Kalmady Vasu said. “It is very important to develop objective, evidence-based tools for these complex disorders that afflict humankind.”



More information:
Sunil Vasu Kalmady et al, Extending schizophrenia diagnostic model to predict schizotypy in first-degree relatives, npj Schizophrenia (2020). DOI: 10.1038/s41537-020-00119-y

Citation:
AI used to predict early symptoms of schizophrenia in relatives of patients (2021, January 26)
retrieved 27 January 2021
from https://medicalxpress.com/news/2021-01-ai-early-symptoms-schizophrenia-relatives.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Leave a Reply

Your email address will not be published. Required fields are marked *